Alexandria Real Estate Equities (ARE) Stock Price & How to Invest

Alexandria Real Estate Equities is a real estate investment trust that pioneered the life-science real estate niche, building and operating collaborative lab and office campuses in top research clusters such as Boston/Cambridge, San Francisco, San Diego, Seattle, Maryland, and the Research Triangle. Its tenants are biotech firms, large pharmaceutical companies, medical-device makers, academic and government research institutions, and venture-backed startups, which lease specialized lab space that is expensive to build and hard to replicate. As a REIT, Alexandria distributes most of its taxable income as dividends and earns returns through rent, development of new campuses, and its strategic venture investments in the life-science ecosystem.

The investment picture in 2026 is defined by a tough operating backdrop. A slowdown in biotech funding and a wave of new lab supply has pushed occupancy down and pressured leasing, with Alexandria reporting an unusually weak first quarter that included no public-biotech lease signings. Revenue has kept sliding: ~$671 million in the first quarter and ~$663 million in the second, down ~12% year over year, for trailing twelve-month revenue of ~$2.84 billion. GAAP results swing with impairments and gains (a ~$1.08 billion loss in the fourth quarter of 2025, a ~$359 million profit in the first quarter of 2026 and a ~$74 million loss in the second), so trailing net income is about -$1.03 billion. Management has responded by focusing on its highest-quality mega-campuses, selling non-core assets, and in late September 2026 closing an amended and restated $5.0 billion unsecured line of credit. The stock closed at $41.87 on October 16, 2026, down ~14.5% year to date, ~44% over a year and ~21% in the past month, near the bottom of a $39.41 to $78.51 52-week range, after BMO downgraded it to underperform and Jefferies and BNP Paribas cut targets. At ~0.46x book value and a ~6.8% yield, the debate centers on whether the life-science leasing cycle recovers before vacancy and debt weigh further on cash flow. Third-quarter results are scheduled for October 26, 2026.

The near-term risk is a weak leasing environment: occupancy fell to roughly 87.7% in early 2026 amid biotech funding pressure, known lease expirations, and new lab supply, and the first quarter saw no public-biotech lease signings for the first time in company history. Rising vacancy, tenant credit stress among cash-burning biotechs, and mark-to-market rent risk could pressure FFO if the cycle does not recover. As a capital-intensive REIT, Alexandria carries meaningful debt, so higher-for-longer interest rates raise refinancing and development costs. Concentration in a single property type means a prolonged life-science downturn would hit it harder than a diversified landlord. Any dividend adjustment or further asset sales at depressed prices would also weigh on sentiment. Revenue fell ~12% year over year in the second quarter of 2026, total debt is ~$13.2 billion against ~$470 million of cash, and analyst sentiment has turned more negative, with BMO moving to underperform in October 2026 and BNP Paribas setting a $40 target. The consensus rating is hold, with a mean target near $51.93.

14 analysts publish price targets on ARE, averaging $51.93 against a $41.60 price as of October 2026, or +24.8%. The published targets run from $40.00 to $60.00, a moderate spread, and the ratings split 2 buy, 10 hold, 4 sell. Over the last six months there have been 7 raises and 3 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ARE forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Alexandria Real Estate Equities. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Mega-campus concentration. Alexandria is concentrating capital in large, amenity-rich campuses in the deepest research clusters, betting that top-tier tenants consolidate into the best locations. The most optimistic published target, $60.00, assumes this works close to its best case.

The case against. The near-term risk is a weak leasing environment: occupancy fell to roughly 87.7% in early 2026 amid biotech funding pressure, known lease expirations, and new lab supply, and the first quarter saw no public-biotech lease signings for the first time in company history. The most pessimistic target, $40.00, is roughly what ARE is worth if this bites instead.

Read the full bull and bear case on ARE, including what would have to change to break either one. Walnut is not an investment adviser.

No. Alexandria Real Estate Equities (ARE) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Alexandria Real Estate Equities's investor relations page or your broker.

• Revenue (TTM): ~$2.84B; Q2 2026 ~$663M, down ~12% year over year
• Net income (TTM, GAAP): ~-$1.03B, driven by impairments; Q2 2026 ~-$74M
• FFO per share (2026 guidance midpoint, given earlier in 2026): ~$6.40; check the October update
• Dividend: $0.72 quarterly ($2.88 annual), yield ~6.8%
• Price / book: ~0.46x
• Market cap: ~$7.2B at $41.87 (Oct 16, 2026)
• Balance sheet: Debt ~$13.2B, cash ~$470M; EV/EBITDA ~13x

For a REIT like Alexandria, FFO is the key earnings measure rather than GAAP EPS or P/E, because GAAP results are swamped by depreciation and impairments. Against the ~$6.40 FFO midpoint guided earlier in 2026, the $41.87 price is roughly 6.5x, and the stock trades at under half of book value, both well below its historical range and a sign of how much occupancy risk the market is pricing. Third-quarter results on October 26, 2026 will update both FFO guidance and leasing trends.

Other names that sit close to ARE: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get ARE exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ARE sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ARE fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

ARE is a specialized life-science landlord trading at about half its book value and a ~6.8% yield while it works through soft biotech leasing, elevated vacancy and falling revenue. After a ~21% drop in the month to October 16, 2026 and a BMO downgrade to underperform, third-quarter results on October 26 are the next read on whether the leasing cycle is turning.

Whether ARE is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ARE a buy or a sell?, and where the stock could go from here in the ARE stock forecast.

For income investors, whether ARE pays a dividend and how the payout looks is covered in does ARE pay a dividend? And to weigh ARE against a peer, read the full side-by-side comparisons: ARE vs VTR and ARE vs WELL.